Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen
Status: Archived
Highlands Oncology Group
mi
from
Springdale, AR
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen
Status: Archived
Updated: 1/1/1970
Highlands Oncology Group
mi
from
Springdale, AR
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen
Status: Archived
Tulane University Medical Center
mi
from
New Orleans, LA
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen
Status: Archived
Updated: 1/1/1970
Tulane University Medical Center
mi
from
New Orleans, LA
Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer
Impact of Dedicated Breast PET Imaging vs. Conventional Two-View Digital Mammography on Recall Rates and Cancer Detection as a Screening Examination in Underserved Women
Status: Archived
Boston University Cancer Research Center
mi
from
Boston, MA
Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer
Impact of Dedicated Breast PET Imaging vs. Conventional Two-View Digital Mammography on Recall Rates and Cancer Detection as a Screening Examination in Underserved Women
Status: Archived
Updated: 1/1/1970
Boston University Cancer Research Center
mi
from
Boston, MA
Laboratory Study Using Tumor Tissue Samples From Women With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Laboratory Study Using Tumor Tissue Samples From Women With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Arizona Clinical Research Center, Inc.
mi
from
Tucson, AZ
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
Multidrug Resistance Proteins in Patients Enrolled in Clinical Trials Outside of the National Cancer Institute Center for Cancer Research
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
Study of Angiogenesis Proteins and Tumor Markers in Inflammatory Breast Cancer Tissue Samples
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
The George Washington University Hospital
mi
from
Washington,
Study of Angiogenesis Proteins and Tumor Markers in Inflammatory Breast Cancer Tissue Samples
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
Updated: 1/1/1970
The George Washington University Hospital
mi
from
Washington,
Study of Angiogenesis Proteins and Tumor Markers in Inflammatory Breast Cancer Tissue Samples
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Study of Angiogenesis Proteins and Tumor Markers in Inflammatory Breast Cancer Tissue Samples
Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Sinai-Grace Hospital
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Updated: 1/1/1970
Sinai-Grace Hospital
mi
from
Detroit, MI
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Updated: 1/1/1970
Fox Chase Cancer Center
mi
from
Philadephia, PA
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of MM-111 in Patients With Advanced Her2 Positive Cancers
A Phase 1-2 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Positive Cancers
Status: Archived
Updated: 1/1/1970
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Eastern Connecticut Hematology & Oncology
mi
from
Norwich, CT
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Eastern Connecticut Hematology & Oncology
mi
from
Norwich, CT
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Aventura Hospital and Medical Center
mi
from
Aventura, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Aventura Hospital and Medical Center
mi
from
Aventura, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists
mi
from
Fort Myers, FL
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Mercy Hospital
mi
from
Portland, ME
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Mercy Hospital
mi
from
Portland, ME
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Mid Ohio Oncology/Hematology, Inc.
mi
from
Columbus, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Mid Ohio Oncology/Hematology, Inc.
mi
from
Columbus, OH
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Fairfax Northern Virginia Hem-Onc
mi
from
Fairfax, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Fairfax Northern Virginia Hem-Onc
mi
from
Fairfax, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Virginia Cancer Institute
mi
from
Richmond, VA
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Virginia Cancer Institute
mi
from
Richmond, VA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
101 Carnegie Center
mi
from
Princeton, NJ
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
Updated: 1/1/1970
101 Carnegie Center
mi
from
Princeton, NJ
Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy
Breast MRI Screening in High-Risk Women After Mantle Radiation Therapy for Lymphoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy
Breast MRI Screening in High-Risk Women After Mantle Radiation Therapy for Lymphoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Status: Archived
Mroz-Baier Breast Care Clinic
mi
from
Memphis, TN
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Status: Archived
Updated: 1/1/1970
Mroz-Baier Breast Care Clinic
mi
from
Memphis, TN
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Status: Archived
The Rose Diagnostic Center
mi
from
Houston, TX
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Status: Archived
Updated: 1/1/1970
The Rose Diagnostic Center
mi
from
Houston, TX
Screening in Myocardial Perfusion Patients
Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Screening in Myocardial Perfusion Patients
Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer
Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer
Status: Archived
Trinitas Comprehensive Cancer Center
mi
from
Elizabeth, NJ
Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer
Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer
Status: Archived
Updated: 1/1/1970
Trinitas Comprehensive Cancer Center
mi
from
Elizabeth, NJ
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Updated: 1/1/1970
Barnes Jewish Hospital - Washington University
mi
from
St. Louis, MO
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors
Status: Archived
Pfizer Investigational Site
mi
from
Duluth, MN
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Duluth, MN
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Status: Archived
Tulane University Medical Center
mi
from
New Orleans, LA
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Status: Archived
Updated: 1/1/1970
Tulane University Medical Center
mi
from
New Orleans, LA
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY